12 Hrs
Source:
الاقتصادية
_1777294237270_124456903.png&w=64&q=75){kind=small}
Source: الاقتصادية
12 Hrsالاقتصادية
Source: الاقتصادية
12 HrsReady to play
Ready to play
Alvion Pharma Company expects to achieve cumulative revenues of no less than 800 million Riyals over five years from the launch of the "Terzibatide" drug in the Middle East and North Africa markets, under an exclusive licensing agreement with an Indian company. The drug, a generic version of "Mongaru Quik Ben," will be marketed after the patent expires, and the agreement includes exclusive rights for registration and marketing for a period of 10 years, with renewable options, as well as the potential for future technology transfer for manufacturing. The aim of the agreement is to strengthen the company's portfolio of "GLP-1" drugs for treating diabetes and obesity, and to support its expansion in line with Saudi Arabia's Vision 2030.
Notice: This Is an AI-Generated Summary
Comments (0)